Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products

W. A. Germishuizen, D. C. Gyure, D. Stubbings, T. Burnouf

研究成果: 雜誌貢獻文章

17 引文 (Scopus)

摘要

Polyvalent immunoglobulin G (IgG) products obtained by fractionation of human plasma are used to treat a broad range of conditions, including immunodeficiency syndromes and autoimmune, inflammatory, and infectious diseases. Recent incidences of increased thromboembolic events (TEEs) associated with intravenous (IV) IgG (IVIG) led to recalls of some products and increased regulatory oversight of manufacturing processes in order to ensure that products are essentially free of procoagulant/thrombogenic plasma protein contaminants. Laboratory investigations have now identified activated factor XI (FXIa) as the likely causative agent of IVIG-related TEEs. Quantification of the thrombogenic potential is becoming a requirement made to fractionators (a) to validate the capacity of IVIG and subcutaneous IgG manufacturing processes to remove procoagulant contaminants and (b) to establish the safety of the final products. However, in the absence of a recommended test by the main regulatory authorities, several analytical approaches have been evaluated by fractionators, regulators, and university groups. This review focuses on the scientific rationale, merits, and applications of several analytical methods of quantifying the thrombogenic potential of IgG products and intermediates to meet the latest regulatory requirements.
原文英語
頁(從 - 到)260-270
頁數11
期刊Biologicals
42
發行號5
DOIs
出版狀態已發佈 - 九月 1 2014

指紋

Plasma (human)
Immunoglobulins
Immunoglobulin G
Impurities
Fractionation
Proteins
Plasmas
Factor XIa
Product Recalls and Withdrawals
Intravenous Immunoglobulins
Autoimmune Diseases
Communicable Diseases
Blood Proteins
Safety
Incidence

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Bioengineering
  • Immunology and Microbiology(all)
  • Pharmacology
  • Medicine(all)

引用此文

Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. / Germishuizen, W. A.; Gyure, D. C.; Stubbings, D.; Burnouf, T.

於: Biologicals, 卷 42, 編號 5, 01.09.2014, p. 260-270.

研究成果: 雜誌貢獻文章

Germishuizen, W. A. ; Gyure, D. C. ; Stubbings, D. ; Burnouf, T. / Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. 於: Biologicals. 2014 ; 卷 42, 編號 5. 頁 260-270.
@article{eddcfa02b30d43549449c888db3ef5d4,
title = "Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products",
abstract = "Polyvalent immunoglobulin G (IgG) products obtained by fractionation of human plasma are used to treat a broad range of conditions, including immunodeficiency syndromes and autoimmune, inflammatory, and infectious diseases. Recent incidences of increased thromboembolic events (TEEs) associated with intravenous (IV) IgG (IVIG) led to recalls of some products and increased regulatory oversight of manufacturing processes in order to ensure that products are essentially free of procoagulant/thrombogenic plasma protein contaminants. Laboratory investigations have now identified activated factor XI (FXIa) as the likely causative agent of IVIG-related TEEs. Quantification of the thrombogenic potential is becoming a requirement made to fractionators (a) to validate the capacity of IVIG and subcutaneous IgG manufacturing processes to remove procoagulant contaminants and (b) to establish the safety of the final products. However, in the absence of a recommended test by the main regulatory authorities, several analytical approaches have been evaluated by fractionators, regulators, and university groups. This review focuses on the scientific rationale, merits, and applications of several analytical methods of quantifying the thrombogenic potential of IgG products and intermediates to meet the latest regulatory requirements.",
keywords = "FXIa, IVIG, Procoagulant, SCIG, Thrombosis",
author = "Germishuizen, {W. A.} and Gyure, {D. C.} and D. Stubbings and T. Burnouf",
year = "2014",
month = "9",
day = "1",
doi = "10.1016/j.biologicals.2014.04.002",
language = "English",
volume = "42",
pages = "260--270",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products

AU - Germishuizen, W. A.

AU - Gyure, D. C.

AU - Stubbings, D.

AU - Burnouf, T.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Polyvalent immunoglobulin G (IgG) products obtained by fractionation of human plasma are used to treat a broad range of conditions, including immunodeficiency syndromes and autoimmune, inflammatory, and infectious diseases. Recent incidences of increased thromboembolic events (TEEs) associated with intravenous (IV) IgG (IVIG) led to recalls of some products and increased regulatory oversight of manufacturing processes in order to ensure that products are essentially free of procoagulant/thrombogenic plasma protein contaminants. Laboratory investigations have now identified activated factor XI (FXIa) as the likely causative agent of IVIG-related TEEs. Quantification of the thrombogenic potential is becoming a requirement made to fractionators (a) to validate the capacity of IVIG and subcutaneous IgG manufacturing processes to remove procoagulant contaminants and (b) to establish the safety of the final products. However, in the absence of a recommended test by the main regulatory authorities, several analytical approaches have been evaluated by fractionators, regulators, and university groups. This review focuses on the scientific rationale, merits, and applications of several analytical methods of quantifying the thrombogenic potential of IgG products and intermediates to meet the latest regulatory requirements.

AB - Polyvalent immunoglobulin G (IgG) products obtained by fractionation of human plasma are used to treat a broad range of conditions, including immunodeficiency syndromes and autoimmune, inflammatory, and infectious diseases. Recent incidences of increased thromboembolic events (TEEs) associated with intravenous (IV) IgG (IVIG) led to recalls of some products and increased regulatory oversight of manufacturing processes in order to ensure that products are essentially free of procoagulant/thrombogenic plasma protein contaminants. Laboratory investigations have now identified activated factor XI (FXIa) as the likely causative agent of IVIG-related TEEs. Quantification of the thrombogenic potential is becoming a requirement made to fractionators (a) to validate the capacity of IVIG and subcutaneous IgG manufacturing processes to remove procoagulant contaminants and (b) to establish the safety of the final products. However, in the absence of a recommended test by the main regulatory authorities, several analytical approaches have been evaluated by fractionators, regulators, and university groups. This review focuses on the scientific rationale, merits, and applications of several analytical methods of quantifying the thrombogenic potential of IgG products and intermediates to meet the latest regulatory requirements.

KW - FXIa

KW - IVIG

KW - Procoagulant

KW - SCIG

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84908151408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908151408&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2014.04.002

DO - 10.1016/j.biologicals.2014.04.002

M3 - Article

C2 - 25096922

AN - SCOPUS:84908151408

VL - 42

SP - 260

EP - 270

JO - Biologicals

JF - Biologicals

SN - 1045-1056

IS - 5

ER -